NRx Pharmaceuticals to participate in H.C. Wainwright's annual conference.

NRx Pharmaceuticals and HOPE Therapeutics announced that Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals, will participate in a fireside chat at H.C. Wainwright's 27th Annual Global Investment Conference on September 8, 2025. The webcast will be available on the company's website, and a replay will be accessible for 30 days following the event. Management will also participate in one-on-one investor meetings throughout the conference.

WILMINGTON, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, Inc. ("HOPE", or the "Company"), announced that Jonathan Javitt, M.D., M.P.H., Chairman and Chief Executive Officer of NRx Pharmaceuticals, will participate in a fireside chat at H.C. Wainwright’s 27th Annual Global Investment Conference on Monday, September 8, 2025, from 4:30 to 5:00 PM ET [1].

The fireside chat will be webcast on the Events page of the Investors section of the Company’s website at https://ir.nrxpharma.com/events. A replay of the webcast will be available two hours after the event and will be accessible for 30 days following the event [1].

In addition to the fireside chat, management will also be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the NRx Pharmaceuticals management team should contact their H.C. Wainwright representative or Brian Korb at astr Partners, brian.korb@astrpartners.com [1].

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression [1].

About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company, which plans to build a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy [1].

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements [1].

For further information, contact Matthew Duffy, Co-CEO, Hope Therapeutics, Inc. Chief Business Officer, NRx Pharmaceuticals, Inc. at mduffy@nrxpharma.com or Brian Korb, Managing Partner, astr partners at (917) 653-5122, brian.korb@astrpartners.com [1].

References:
[1] https://www.morningstar.com/news/globe-newswire/9522339/nrx-pharmaceuticals-nasdaqnrxp-to-participate-in-a-fireside-chat-at-hc-wainwrights-27th-annual-global-investment-conference-on-monday-september-8th